Comparison of sildenafil with strontium fructose diphosphate in improving erectile dysfunction against upregulated cavernosal NADPH oxidase, protein kinase Cε, and endothelin system in diabetic rats

Journal of Pharmacy and Pharmacology

Volumn 64, Issue 2, 2012, Pages 244-251

  Xu, Ming ^a   Tang, Yi Qun ^a   Dai, De Zai ^a   Zheng, Yu Feng ^a   Cheng, Yu Si ^a   Zhang, Qi ^b   Dai, Yin ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b NANJING TECH UNIVERSITY   (China)

Author keywords

corpus cavernosum; endothelin 1 (ED 1); erectile dysfunction; NADPH oxidase; strontium fructose diphosphate (FDP Sr)

Indexed keywords

AGENTS ACTING ON THE GENITAL SYSTEM; BIOLOGICAL MARKER; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; GLUCOSE; MALONALDEHYDE; MESSENGER RNA; PROTEIN KINASE C EPSILON; PROTEIN P22; PROTEIN P47; PROTEIN P67; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SILDENAFIL; STRONTIUM FRUCTOSE 1,6 DIPHOSPHATE; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIN RECEPTOR TYPE A GENE; ENDOTHELIN RECEPTOR TYPE B GENE; ENZYME ACTIVATION; ERECTILE DYSFUNCTION; GENE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GLUCOSE BLOOD LEVEL; MALE; NONHUMAN; P22 GENE; P47 GENE; P67 GENE; PENILE BLOOD FLOW; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; RAT; RECEPTOR GENE; STREPTOZOCIN DIABETES; VASODILATATION;

ANIMALS; BLOOD GLUCOSE; BLOTTING, WESTERN; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; ENDOTHELIN-1; ERECTILE DYSFUNCTION; FRUCTOSEDIPHOSPHATES; MALE; MALONDIALDEHYDE; NADPH OXIDASE; PIPERAZINES; PROTEIN KINASE C-EPSILON; PURINES; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SULFONES; SUPEROXIDE DISMUTASE; UP-REGULATION; VASODILATOR AGENTS;

EID: 84855435624     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2011.01390.x     Document Type: Article

References (32)

1. Moore CR, Wang R,. Pathophysiology and treatment of diabetic erectile dysfunction. Asian J Androl 2006; 8: 675-684. (Pubitemid 44869615)
2. Corona G, et al,. Organic, relational and psychological factors in erectile dysfunction in men with diabetes mellitus. Eur Urol 2004; 46: 222-228. (Pubitemid 38902742)
3. Dorsey P, et al,. Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction. Expert Opin Pharmacother 2010; 11: 1109-1122.
4. Suetomi T, et al,. Negative impact of metabolic syndrome on the responsiveness to sildenafil in Japanese men. J Sex Med 2008; 5: 1443-1450. (Pubitemid 351803110)
5. Angulo J, et al,. Diabetes exacerbates the functional deficiency of NO/cGMP pathway associated with erectile dysfunction in human corpus cavernosum and penile arteries. J Sex Med 2010; 7: 758-768.
6. Ryu JK, et al,. The role of free radical in the pathogenesis of impotence in streptozotocin-induced diabetic rats. Yonsei Med J 2003; 44: 236-241.
7. Bivalacqua TJ, et al,. Superoxide anion production in the rat penis impairs erectile function in diabetes: influence of in vivo extracellular superoxide dismutase gene therapy. J Sex Med 2005; 2: 187-197; discussion 197-188. (Pubitemid 40468173)
8. Jin L, et al,. NADPH oxidase activation: a mechanism of hypertension-associated erectile dysfunction. J Sex Med 2008; 5: 544-551. (Pubitemid 351337880)
9. Jin L, Burnett AL,. NADPH oxidase: recent evidence for its role in erectile dysfunction. Asian J Androl 2008; 10: 6-13.
10. Thallas-Bonke V, et al,. Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway. Diabetes 2008; 57: 460-469.
11. Li N, et al,. Endothelin receptor antagonist CPU0213 and vitamin E reverse downregulation of FKBP12.6 and SERCA2a: a role of hyperphosphorylation of PKCepsilon. Eur J Pharmacol 2008; 591: 211-218.
12. Cheng YS, et al,. Isoproterenol disperses distribution of NADPH oxidase, MMP-9, and pPKCepsilon in the heart, which are mitigated by endothelin receptor antagonist CPU0213. Acta Pharmacol Sin 2009; 30: 1099-1106.
13. Xu M, et al,. Normalizing NADPH oxidase contributes to attenuating diabetic nephropathy by the dual endothelin receptor antagonist CPU0213 in rats. Am J Nephrol 2009; 29: 252-256.
14. Qi MY, et al,. Total triterpene acids, active ingredients from Fructus Corni, attenuate diabetic cardiomyopathy by normalizing ET pathway and expression of FKBP12.6 and SERCA2a in streptozotocin-rats. J Pharm Pharmacol 2008; 60: 1687-1694.
15. Ganz MB, Seftel A,. Glucose-induced changes in protein kinase C and nitric oxide are prevented by vitamin E. Am J Physiol Endocrinol Metab 2000; 278: E146-E152. (Pubitemid 30101932)
16. Diaz-Ruiz R, et al,. Mitochondrial oxidative phosphorylation is regulated by fructose 1,6-bisphosphate. A possible role in Crabtree effect induction? J Biol Chem 2008; 283: 26948-26955.
17. Tang XY, et al,. Effects of strontium fructose 1,6-diphosphate on expression of apoptosis-related genes and oxidative stress in testes of diabetic rats. Int J Urol 2008; 15: 251-256.
18. Feng Y, et al,. Strontium fructose 1,6-diphosphate rescues adenine-induced male hypogonadism and upregulates the testicular endothelin-1 system. Clin Exp Pharmacol Physiol 2007; 34: 1131-1137. (Pubitemid 47416353)
19. Xu M, et al,. Upregulated NADPH oxidase contributes to diabetic testicular complication and is relieved by strontium fructose 1,6-diphosphate. Exp Clin Endocrinol Diabetes 2010; 118: 459-465.
20. Jeong KH, et al,. Effects of sildenafil on oxidative and inflammatory injuries of the kidney in streptozotocin-induced diabetic rats. Am J Nephrol 2009; 29: 274-282.
21. Jackson G,. Sexual dysfunction and diabetes. Int J Clin Pract 2004; 58: 358-362. (Pubitemid 38714441)
22. Hu C, et al,. Argirein alleviates diabetic nephropathy through attenuating NADPH oxidase, Cx43, and PERK in renal tissue. Naunyn Schmiedebergs Arch Pharmacol 2011; 383: 309-319.
23. Malavige LS, Levy JC,. Erectile dysfunction in diabetes mellitus. J Sex Med 2009; 6: 1232-1247.
24. Peng HJ, et al,. The separate roles of endothelin receptors participate in remodeling of matrix metalloproteinase and connexin 43 of cardiac fibroblasts in maladaptive response to isoproterenol. Eur J Pharmacol 2010; 634: 101-106.
25. Bivalacqua TJ, et al,. Endothelial dysfunction in erectile dysfunction: role of the endothelium in erectile physiology and disease. J Androl 2003; 24: S17-S37. (Pubitemid 37370524)
26. Morano S, et al,. Circulating monocyte oxidative activity is increased in patients with type 2 diabetes and erectile dysfunction. J Urol 2007; 177: 655-659. (Pubitemid 46054025)
27. Shukla N, et al,. Calcium and the replication of human vascular smooth muscle cells: studies on the activation and translocation of extracellular signal regulated kinase (ERK) and cyclin D1 expression. Eur J Pharmacol 2005; 509: 21-30. (Pubitemid 40248781)
28. Claudino MA, et al,. Upregulation of gp91phox subunit of NAD(P)H oxidase contributes to erectile dysfunction caused by long-term nitric oxide inhibition in rats: reversion by regular physical training. Urology 2010; 75: 961-967.
29. Chang S, et al,. Increased contractility of diabetic rabbit corpora smooth muscle in response to endothelin is mediated via Rho-kinase beta. Int J Impot Res 2003; 15: 53-62. (Pubitemid 36356359)
30. Khan MA, et al,. Normal and pathological erectile function: the potential clinical role of endothelin-1 antagonists. Curr Drug Targets 2000; 1: 247-260.
31. De Young L, et al,. Effect of PDE5 inhibition combined with free oxygen radical scavenger therapy on erectile function in a diabetic animal model. Int J Impot Res 2003; 15: 347-354. (Pubitemid 37376940)
32. Vicari E, et al,. Endothelial antioxidant administration ameliorates the erectile response to PDE5 regardless of the extension of the atherosclerotic process. J Sex Med 2010; 7: 1247-1253.